Is KPV FDA-approved?

The α-MSH family has three approved drugs — and none of them is KPV

KPV is a tripeptide: lysine, proline, valine. Those are the last three residues of α-melanocyte-stimulating hormone, a thirteen-amino-acid hormone, which is why the research literature also writes the fragment as α-MSH(11–13). What KPV is covers the molecule itself — where it comes from, and what it is routinely mistaken for. The relationship to the hormone is real, and it is the source of most of the confusion on this question, because the melanocortin family has in fact reached the US market, three times in two years.

SCENESSE (afamelanotide), NDA 210797, approved to Clinuvel on 8 October 2019, increases pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. VYLEESI (bremelanotide), NDA 210557, approved to AMAG Pharmaceuticals on 21 June 2019, treats acquired, generalized hypoactive sexual desire disorder in premenopausal women. IMCIVREE (setmelanotide), NDA 213793, approved to Rhythm Pharmaceuticals on 25 November 2020, is for chronic weight management in obesity caused by POMC, PCSK1 or LEPR deficiency confirmed by genetic testing.

Read those three indications again. Photoprotection, sexual desire, a small set of rare genetic obesity syndromes. Not one of them is inflammation and not one is wound healing — the uses KPV is sold for, and the pair of uses the advisory committee voted on in July 2026. Each of the three is an engineered molecule with receptor pharmacology worked out to the point of a label claim, a United States Adopted Name, an International Nonproprietary Name and a completed New Drug Application behind it. KPV has none of those things. The family’s approval record is not KPV’s approval record, and citing it answers a different question.

One detail in that list is worth stopping on, and it sits in the FDA’s own label. Afamelanotide’s sequence is printed there as Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. The approved drug ends in exactly the three residues sold as KPV. That is neither a loophole nor an endorsement. Approval attaches to a drug product, and the ingredient the FDA reviewed was the whole tridecapeptide, as a subcutaneous implant, for one rare disease. The same three residues on their own have never been through any part of that process.

KPV does not work the way the approved drugs work

This is what makes borrowing the family’s evidence untenable rather than merely loose. The three approved drugs are receptor agonists with a defined target. KPV’s anti-inflammatory activity is attributed to something else — and the published literature does not agree on what.

A 2021 review in Pharmaceuticals describes the C-terminal tripeptides of α-MSH as keeping anti-inflammatory properties “with no pigmentary effects” — that is, without the melanocortin signalling that defines afamelanotide — while reporting KPV acting through MC3R in human bronchial epithelial cells. Work on the gut attributes the effect instead to uptake by PepT1, an oligopeptide transporter over-expressed on colonic epithelium and macrophages during colitis, which is the basis of the oral nanoparticle systems built around the peptide. A 2019 review in Frontiers in Endocrinology notes α-MSH(11–13) attenuating cerebral inflammation “probably by targeting the MC1R” — the hedge is the review’s own.

Three candidate mechanisms, three tissues, no settled answer. Mechanism is not itself a requirement for approval; the FDA approves on evidence of effect, not on explanation. But mechanism is what tells a sponsor which trial to run, at what dose and by which route, and what else the drug is likely to touch. Three answers in three tissues is a measure of how early this work still is.

What the KPV evidence actually is

The 2021 review’s own inventory of KPV experiments is a fair summary of the field: immortalized human bronchial epithelial cells, mice with experimentally induced colitis, and corneal wound healing in rabbits. The more recent gut work has the same shape — mouse models of DSS-induced colitis, with the peptide carried in hyaluronic-acid or co-assembled nanoparticles to get it to inflamed tissue. These are competent studies. They are also, without exception, laboratory and animal studies.

We have not identified a registered clinical trial of KPV in humans, under that name or as α-MSH(11–13), for any indication. That is a weaker claim than “none exists”, and it is deliberately weaker: it is what the public record we can verify supports.

One mismatch deserves naming, because the pages selling KPV do not mention it. The routes that carry the published evidence are oral and topical — that is what the nanoparticle work and the rabbit corneal work are. What circulates on the gray market is largely injectable. The evidence and the product are not describing the same thing.

What approval would actually require

A drug reaches the US market through an Investigational New Drug application, then Phase 1, 2 and 3 trials, then a New Drug Application or Biologics License Application that the FDA reviews and approves. No sponsor has begun that sequence for KPV.

The chemistry half is where the FDA’s own reviewers were blunt. At the July 2026 meeting, review staff recommended against all seven peptides on the agenda — KPV included — on grounds that had little to do with whether they work: no United States Adopted Name, incomplete physical and chemical characterization, unknown impurity profiles arising from solid-phase peptide synthesis, and a risk of immunogenicity from peptide aggregation in injectable products. The committee voted 8–6 with one abstention to recommend KPV anyway, against that advice.

Nothing published about KPV answers any of those four objections. A three-residue peptide still needs a nonproprietary name, a characterization file, a documented impurity profile from whatever synthesis produced it and — if it is to be injected — an aggregation and immunogenicity assessment. Being short makes some of that work easier. It does not make it done.

Size is not what is stopping KPV

The usual defence at this point is that KPV is only three amino acids, so the questions asked of a large biologic should not apply to it. The approved drugs in its own family dispose of that argument, and their FDA labels say so in the Description section of each. Afamelanotide is “a synthetic tridecapeptide” — thirteen residues. Bremelanotide is “a synthetic, cyclic heptapeptide” — seven, fewer than α-MSH itself. Setmelanotide is “an 8 amino acid cyclic peptide analog of endogenous melanocortin peptide α-MSH”. Two of the three approved melanocortin drugs are shorter than the hormone they come from.

Short peptides reach the US market routinely. What separates them from KPV is not length. It is that somebody filed for them.

Compounding eligibility is not approval — and KPV’s indication is the widest of the seven

Approval and compounding are separate statutory pathways, not two stages of one. Approval runs through section 505 of the Federal Food, Drug, and Cosmetic Act. Compounding runs through section 503A, which lets a licensed pharmacy prepare a medicine from a bulk substance on an FDA list precisely because the substance is not an approved drug. A final rule adding KPV to that list would not make KPV approved; it would make it compoundable. Our explainer on US peptide regulation sets out how the two pathways differ, and why the rulemaking timeline runs to 2027 at the earliest.

The distinction bites harder for KPV than for anything else on the July agenda, because of what the committee was asked to vote on. Each substance was judged against a named use: BPC-157 against ulcerative colitis, TB-500 against wound healing. KPV was put to the committee for wound healing and inflammatory conditions — one disease process and one open-ended category. An approval is granted indication by indication, with trial evidence to match each one. A listing carries no indication at all once a prescriber writes the prescription. The distance between what was voted on and what KPV would be used for is widest here.

Primary sources: FDA approval letter and approval package, NDA 210797 SCENESSE (afamelanotide), 8 October 2019, Clinuvel · FDA approval package, NDA 210557 VYLEESI (bremelanotide), 21 June 2019, AMAG Pharmaceuticals · FDA approval package, NDA 213793 IMCIVREE (setmelanotide), 25 November 2020, Rhythm Pharmaceuticals · structures and sequences quoted from the Description sections of the FDA-approved labels for SCENESSE, VYLEESI and IMCIVREE · EMA EPAR, Scenesse, EU marketing authorisation 22 December 2014 ·Dinparastisaleh R, Mirsaeidi M, Pharmaceuticals 2021;14(1):45 · Tao Y-X et al., Front Endocrinol 2019;10:683 · Front Pharmacol 2024;15:1442876 (PepT1-targeted KPV nanoparticles, murine colitis) · FDA Advisory Committee Calendar and Federal Register docket FDA-2025-N-6895 (PCAC, 23–24 July 2026) · sections 503A and 505 of the FD&C Act.